These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25805928)

  • 21. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review.
    Sahebkar A; Sancho E; Abelló D; Camps J; Joven J
    J Cell Physiol; 2018 Feb; 233(2):849-855. PubMed ID: 28063221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis.
    Miller MH; Walsh SV; Atrih A; Huang JT; Ferguson MA; Dillon JF
    J Gastroenterol Hepatol; 2014 Oct; 29(10):1839-47. PubMed ID: 24750217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
    Yoneda M; Imajo K; Takahashi H; Ogawa Y; Eguchi Y; Sumida Y; Yoneda M; Kawanaka M; Saito S; Tokushige K; Nakajima A
    J Gastroenterol; 2018 Feb; 53(2):181-196. PubMed ID: 29177681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification.
    Burt AD; Lackner C; Tiniakos DG
    Semin Liver Dis; 2015 Aug; 35(3):207-20. PubMed ID: 26378639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Kelley CE; Brown AJ; Diehl AM; Setji TL
    World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease.
    Suh JB; Kim SM; Cho GJ; Choi KM
    Scand J Gastroenterol; 2014 Aug; 49(8):979-85. PubMed ID: 24957697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
    Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
    Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.